vs
Broadstone Net Lease, Inc.（BNL）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Broadstone Net Lease, Inc.的1.7倍（$207.3M vs $121.4M），Broadstone Net Lease, Inc.净利率更高（38.2% vs -62.0%，领先100.2%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 11.7%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 7.1%）
Broadstone Net Lease, Inc.是一家房地产投资信托公司，主要在美国市场收购、持有并管理单一租户商业地产资产组合，覆盖工业设施、医疗物业、零售门店、办公空间等核心板块，所有物业均与租户签订长期净租赁协议。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
BNL vs RARE — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $121.4M | $207.3M |
| 净利润 | $46.4M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 52.2% | -54.7% |
| 净利率 | 38.2% | -62.0% |
| 营收同比 | 11.7% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $0.24 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | $121.4M | — | ||
| Q4 25 | $118.3M | $207.3M | ||
| Q3 25 | $114.2M | $159.9M | ||
| Q2 25 | $113.0M | $166.5M | ||
| Q1 25 | $108.7M | $139.3M | ||
| Q4 24 | $112.1M | $164.6M | ||
| Q3 24 | $108.4M | $139.5M | ||
| Q2 24 | $105.9M | $147.0M |
| Q1 26 | $46.4M | — | ||
| Q4 25 | $33.1M | $-128.6M | ||
| Q3 25 | $26.5M | $-180.4M | ||
| Q2 25 | $20.2M | $-115.0M | ||
| Q1 25 | $16.7M | $-151.1M | ||
| Q4 24 | $26.4M | $-133.2M | ||
| Q3 24 | $35.6M | $-133.5M | ||
| Q2 24 | $35.3M | $-131.6M |
| Q1 26 | 52.2% | — | ||
| Q4 25 | — | -54.7% | ||
| Q3 25 | — | -106.9% | ||
| Q2 25 | — | -64.8% | ||
| Q1 25 | — | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | — | -94.6% | ||
| Q2 24 | — | -79.1% |
| Q1 26 | 38.2% | — | ||
| Q4 25 | 28.0% | -62.0% | ||
| Q3 25 | 23.2% | -112.8% | ||
| Q2 25 | 17.8% | -69.0% | ||
| Q1 25 | 15.4% | -108.5% | ||
| Q4 24 | 23.5% | -80.9% | ||
| Q3 24 | 32.8% | -95.7% | ||
| Q2 24 | 33.4% | -89.5% |
| Q1 26 | $0.24 | — | ||
| Q4 25 | $0.17 | $-1.28 | ||
| Q3 25 | $0.14 | $-1.81 | ||
| Q2 25 | $0.10 | $-1.17 | ||
| Q1 25 | $0.09 | $-1.57 | ||
| Q4 24 | $0.13 | $-1.34 | ||
| Q3 24 | $0.19 | $-1.40 | ||
| Q2 24 | $0.19 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $20.3M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.0B | $-80.0M |
| 总资产 | $5.8B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | $20.3M | — | ||
| Q4 25 | $30.5M | $421.0M | ||
| Q3 25 | $82.0M | $202.5M | ||
| Q2 25 | $20.8M | $176.3M | ||
| Q1 25 | $9.6M | $127.1M | ||
| Q4 24 | $14.8M | $174.0M | ||
| Q3 24 | $9.0M | $150.6M | ||
| Q2 24 | $18.3M | $480.7M |
| Q1 26 | — | — | ||
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $1.9B | — | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $1.9B | — |
| Q1 26 | $3.0B | — | ||
| Q4 25 | $2.9B | $-80.0M | ||
| Q3 25 | $2.9B | $9.2M | ||
| Q2 25 | $2.9B | $151.3M | ||
| Q1 25 | $2.9B | $144.2M | ||
| Q4 24 | $3.0B | $255.0M | ||
| Q3 24 | $3.0B | $346.8M | ||
| Q2 24 | $3.1B | $432.4M |
| Q1 26 | $5.8B | — | ||
| Q4 25 | $5.7B | $1.5B | ||
| Q3 25 | $5.5B | $1.2B | ||
| Q2 25 | $5.3B | $1.3B | ||
| Q1 25 | $5.2B | $1.3B | ||
| Q4 24 | $5.2B | $1.5B | ||
| Q3 24 | $5.3B | $1.5B | ||
| Q2 24 | $5.3B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.87× | — | ||
| Q3 25 | 0.82× | — | ||
| Q2 25 | 0.73× | — | ||
| Q1 25 | 0.68× | — | ||
| Q4 24 | 0.64× | — | ||
| Q3 24 | 0.65× | — | ||
| Q2 24 | 0.62× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $299.5M | $-99.8M | ||
| Q3 25 | $64.2M | $-91.4M | ||
| Q2 25 | $79.3M | $-108.3M | ||
| Q1 25 | $71.5M | $-166.5M | ||
| Q4 24 | $276.3M | $-79.3M | ||
| Q3 24 | $67.3M | $-67.0M | ||
| Q2 24 | $74.2M | $-77.0M |
| Q1 26 | — | — | ||
| Q4 25 | $269.8M | $-100.8M | ||
| Q3 25 | $58.0M | $-92.7M | ||
| Q2 25 | $76.7M | $-110.7M | ||
| Q1 25 | $57.1M | $-167.8M | ||
| Q4 24 | $259.5M | $-79.5M | ||
| Q3 24 | $60.3M | $-68.6M | ||
| Q2 24 | $74.0M | $-79.0M |
| Q1 26 | — | — | ||
| Q4 25 | 228.1% | -48.6% | ||
| Q3 25 | 50.8% | -58.0% | ||
| Q2 25 | 67.9% | -66.5% | ||
| Q1 25 | 52.5% | -120.5% | ||
| Q4 24 | 231.4% | -48.3% | ||
| Q3 24 | 55.6% | -49.2% | ||
| Q2 24 | 69.9% | -53.7% |
| Q1 26 | — | — | ||
| Q4 25 | 25.1% | 0.5% | ||
| Q3 25 | 5.4% | 0.8% | ||
| Q2 25 | 2.3% | 1.5% | ||
| Q1 25 | 13.2% | 1.0% | ||
| Q4 24 | 15.0% | 0.1% | ||
| Q3 24 | 6.5% | 1.2% | ||
| Q2 24 | 0.2% | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 9.04× | — | ||
| Q3 25 | 2.43× | — | ||
| Q2 25 | 3.93× | — | ||
| Q1 25 | 4.27× | — | ||
| Q4 24 | 10.47× | — | ||
| Q3 24 | 1.89× | — | ||
| Q2 24 | 2.10× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BNL
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
